Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024 11:02 ET
|
Arbutus Biopharma Corporation
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024 11:01 ET
|
Arbutus Biopharma Corporation
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of...
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024 07:30 ET
|
Arbutus Biopharma Corporation
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase...
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024 08:16 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 01, 2024 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its...
Arbutus to Participate in Two Upcoming Investor Conferences
September 03, 2024 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024 07:30 ET
|
Arbutus Biopharma Corporation
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I...
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...